Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Purinostat mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Purinostat mesylate overview

Purinostat mesylate (12l) is under development for the treatment of hematological tumors including but not limited to B-cell lymphoma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), cutaneous T-cell lymphoma, NK/T-cell lymphoma neoplasm (nasal type), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), multiple myeloma, B-cell acute Leukemia, triple-negative Breast cancer, colorectal cancer, urothelial cancer, HER2 negative breast cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal cancer, cervical cancer, hepatocellular carcinoma, renal cell carcinoma,T-cell lymphoma, T-cell acute leukemia after standard regimen therapy, solid tumors including lung cancer, breast cancer, colon cancer etc. It is a dual inhibitor of serine/threonine protein kinase mTOR and histone deacetylase 1 (HDAC1). The drug candidate is designed and synthesized using pyrimidine-pyrazolyl pharmacophore. It is administered through intravenous and parenteral route.

For a complete picture of Purinostat mesylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.